Innovative drugs, as significant outcomes of pharmaceutical research, not only offer patients better treatment options but also reduce long-term burdens on the healthcare system by improving efficacy, reducing adverse reactions, and shortening treatment duration. However, due to the lengthy development cycles and high costs of innovative drugs, challenges arise in determining reasonable pricing and securing insurance coverage. In this context, pharmacoeconomics becomes a crucial tool for evaluating the value of innovative drugs and improving resource allocation efficiency.

To explore how pharmacoeconomic evaluation can support the development, pricing, reimbursement, and market access of innovative drugs, this closed-door symposium will focus on enhancing the affordability and accessibility of innovative drugs worldwide. By leveraging pharmacoeconomic tools, the symposium aims to find a balance between patient needs, drug value, and healthcare payment capabilities, thereby providing scientific guidance for decision-making by governments, enterprises, and healthcare institutions. Organized by the Peking University Institute for Global Health Development, this symposium will offer fresh insights and strategies for innovative drug market access, pricing, and reimbursement, while also advancing the application of pharmacoeconomics in the innovative drug sector to support global drug development in theory and practice.